IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6083949A
(en)
*
|
1995-10-06 |
2000-07-04 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
US6313127B1
(en)
|
1996-02-02 |
2001-11-06 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
GB9602166D0
(en)
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
US5859012A
(en)
*
|
1996-04-03 |
1999-01-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5965578A
(en)
*
|
1996-04-03 |
1999-10-12 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6080870A
(en)
*
|
1996-04-03 |
2000-06-27 |
Merck & Co., Inc. |
Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
US5885995A
(en)
*
|
1996-04-03 |
1999-03-23 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5874452A
(en)
*
|
1996-04-03 |
1999-02-23 |
Merck & Co., Inc. |
Biheteroaryl inhibitors of farnesyl-protein transferase
|
CA2250460A1
(en)
*
|
1996-04-03 |
1997-10-09 |
John H. Hutchinson |
Inhibitors of farnesyl-protein transferase
|
WO1997036892A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2249601A1
(en)
*
|
1996-04-03 |
1997-10-23 |
Thorsten E. Fisher |
Inhibitors of farnesyl-protein transferase
|
CA2250232A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Allen I. Oliff |
A method of treating cancer
|
US5919785A
(en)
*
|
1996-04-03 |
1999-07-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6063930A
(en)
*
|
1996-04-03 |
2000-05-16 |
Merck & Co., Inc. |
Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
|
EP0904080A4
(en)
*
|
1996-04-03 |
2001-08-01 |
Merck & Co Inc |
INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
|
US5922883A
(en)
*
|
1996-04-03 |
1999-07-13 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
WO1997036583A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6001835A
(en)
*
|
1996-04-03 |
1999-12-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5852010A
(en)
*
|
1996-04-03 |
1998-12-22 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5869682A
(en)
*
|
1996-04-03 |
1999-02-09 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780492A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5883105A
(en)
*
|
1996-04-03 |
1999-03-16 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5891889A
(en)
*
|
1996-04-03 |
1999-04-06 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5939557A
(en)
*
|
1996-04-03 |
1999-08-17 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5925651A
(en)
*
|
1996-04-03 |
1999-07-20 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US5780488A
(en)
*
|
1996-04-03 |
1998-07-14 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2250587A1
(en)
*
|
1996-04-03 |
1997-10-09 |
Christopher J. Dinsmore |
Inhibitors of farnesyl-protein transferase
|
DE69718177T2
(de)
*
|
1996-08-14 |
2003-10-23 |
Astrazeneca Ab, Soedertaelje |
Substituierte pyrimidinderivate und ihre pharmazeutische anwendung
|
UA56197C2
(uk)
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Гетероциклічні похідні
|
CA2276081A1
(en)
*
|
1996-12-30 |
1998-07-09 |
Lekhanh O. Tran |
Inhibitors of farnesyl-protein transferase
|
ES2201438T3
(es)
|
1997-02-13 |
2004-03-16 |
Astrazeneca Ab |
Compuestos heterociclicos utiles como inhibidores de la oxido-escualeno-ciclasa.
|
JP2001511798A
(ja)
|
1997-02-13 |
2001-08-14 |
ゼネカ・リミテッド |
オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物
|
US5972942A
(en)
*
|
1997-03-27 |
1999-10-26 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
US6060038A
(en)
*
|
1997-05-15 |
2000-05-09 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
AUPO735997A0
(en)
|
1997-06-17 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Piperazine derivatives
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
EP1019529A4
(en)
*
|
1997-08-27 |
2002-09-11 |
Merck & Co Inc |
METHOD FOR TREATING CANCER
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6103487A
(en)
*
|
1997-08-27 |
2000-08-15 |
Merck & Co., Inc. |
Method of treating cancer
|
AU2286099A
(en)
*
|
1998-02-13 |
1999-08-30 |
Rhone-Poulenc Rorer S.A. |
Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them
|
FR2774985A1
(fr)
*
|
1998-02-13 |
1999-08-20 |
Rhone Poulenc Rorer Sa |
Nouveaux derives de naphthyl disubstitues, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
|
AU5086499A
(en)
*
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for making farnesyl-protein transferase inhibitors
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
EP1165013A4
(en)
*
|
1999-03-03 |
2002-08-07 |
Merck & Co Inc |
PRENYL PROTEIN TRANSFERASE INHIBITORS
|
US6358956B1
(en)
*
|
1999-03-03 |
2002-03-19 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
JP2002538120A
(ja)
*
|
1999-03-03 |
2002-11-12 |
メルク エンド カムパニー インコーポレーテッド |
プレニルタンパク質トランスフェラーゼの阻害剤
|
EP1158982A4
(en)
*
|
1999-03-03 |
2002-06-12 |
Merck & Co Inc |
Prenyl protein transferase inhibitors
|
US6211182B1
(en)
*
|
1999-03-08 |
2001-04-03 |
Schering Corporation |
Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
|
US6458935B1
(en)
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
FR2819510B1
(fr)
*
|
2001-01-18 |
2003-10-31 |
Servier Lab |
Nouveaux composes cyclo[c] azepane, leur procede de preparation et les compositions pharmaceutiques qui le contiennent
|
FR2819512B1
(fr)
*
|
2001-01-18 |
2003-02-21 |
Servier Lab |
Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
FR2819509B1
(fr)
*
|
2001-01-18 |
2004-04-16 |
Servier Lab |
Nouveaux composes cycloheptene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
WO2007031791A1
(en)
|
2005-09-16 |
2007-03-22 |
Arrow Therapeutics Limited |
Biphenyl derivatives and their use in treating hepatitis c
|
SI2343299T1
(sl)
|
2005-12-13 |
2016-06-30 |
Incyte Holdings Corporation |
S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b) pirimidini kot zaviralci janus kinaze
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
AU2007334416A1
(en)
*
|
2006-12-18 |
2008-06-26 |
Novartis Ag |
Imidazoles as aldosterone synthase inhibitors
|
JP4611444B2
(ja)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
|
MX2009009304A
(es)
|
2007-03-01 |
2009-11-18 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso.
|
WO2008144062A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
Csf-1r inhibitors, compositions, and methods of use
|
RS58449B1
(sr)
|
2007-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Upotreba soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h- pirazol-1-il)-3-ciklopentilpropionitrila
|
JP5501227B2
(ja)
|
2007-06-27 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ヒストンデアセチラーゼ阻害剤としての4−カルボキシベンジルアミノ誘導体
|
CA2701116C
(en)
|
2007-10-05 |
2013-02-05 |
Acucela Inc. |
Alkoxy compounds for disease treatment
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
GB0813142D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
GB0813144D0
(en)
|
2008-07-17 |
2008-08-27 |
Glaxo Group Ltd |
Novel compounds
|
ES2740424T3
(es)
|
2009-03-13 |
2020-02-05 |
Agios Pharmaceuticals Inc |
Métodos y composiciones para trastornos relacionados con la proliferación celular
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
CA2758071C
(en)
|
2009-04-06 |
2018-01-09 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
|
KR20120030447A
(ko)
|
2009-05-22 |
2012-03-28 |
인사이트 코포레이션 |
Jak 저해물질로서 3-[4-(7h-피롤로[2,3-d]피리미딘-4-일)-1h-피라졸-1-일]옥탄- 또는 헵탄-니트릴
|
TW201100429A
(en)
|
2009-05-22 |
2011-01-01 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
AU2010266386C1
(en)
|
2009-06-29 |
2017-03-09 |
Agios Pharmaceuticals, Inc. |
Therapeutic compounds and compositions
|
WO2011003103A2
(en)
|
2009-07-02 |
2011-01-06 |
Acucela, Inc. |
Pharmacology of visual cycle modulators
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
EP2488028B1
(en)
|
2009-10-14 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Substituted piperidines that increase p53 activity and the uses thereof
|
ES2594402T3
(es)
|
2009-10-21 |
2016-12-20 |
Agios Pharmaceuticals, Inc. |
Métodos y composiciones para trastornos relacionados con la proliferación celular
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
HUE037077T2
(hu)
|
2010-03-10 |
2018-08-28 |
Incyte Holdings Corp |
Piperidin-4-il-azetidin származékok JAK1-gátlókként
|
JP2013522292A
(ja)
|
2010-03-16 |
2013-06-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
インダゾール化合物およびそれらの使用
|
JP5849312B2
(ja)
|
2010-05-21 |
2016-01-27 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤の局所製剤
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
AU2011285909B2
(en)
|
2010-08-02 |
2016-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2012027236A1
(en)
|
2010-08-23 |
2012-03-01 |
Schering Corporation |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
EP3766975A1
(en)
|
2010-10-29 |
2021-01-20 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
US9221792B2
(en)
|
2010-12-17 |
2015-12-29 |
Agios Pharmaceuticals, Inc |
N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
|
ES2569712T3
(es)
|
2010-12-21 |
2016-05-12 |
Agios Pharmaceuticals, Inc. |
Activadores de PKM2 bicíclicos
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
CN103732592A
(zh)
|
2011-04-21 |
2014-04-16 |
默沙东公司 |
胰岛素样生长因子-1受体抑制剂
|
CA2834602C
(en)
|
2011-05-03 |
2020-10-06 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase activators for use in therapy
|
WO2012151452A1
(en)
|
2011-05-03 |
2012-11-08 |
Agios Pharmaceuticals, Inc |
Pyruvate kinase activators for use in therapy
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
CN102827073A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
CA2856291C
(en)
|
2011-11-17 |
2020-08-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
JP6399660B2
(ja)
*
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
癌治療用組成物および方法
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
MX2015004041A
(es)
|
2012-09-28 |
2015-07-06 |
Merck Sharp & Dohme |
Compuestos novedosos que son inhibidores de erk.
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
BR112015010663B1
(pt)
|
2012-11-15 |
2022-12-06 |
Incyte Holdings Corporation |
Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
|
SI2925888T1
(en)
|
2012-11-28 |
2018-02-28 |
Merck Sharp & Dohme Corp. |
Compounds and methods for the treatment of cancer
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
ES2707355T3
(es)
|
2013-03-06 |
2019-04-03 |
Incyte Holdings Corp |
Procesos y productos intermedios para elaborar un inhibidor de JAK
|
RU2686323C2
(ru)
|
2013-03-13 |
2019-04-25 |
Форма Терапьютикс, Инк. |
Новые соединения и композиции для ингибирования fasn
|
WO2015003360A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
WO2015006591A1
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
|
WO2015003355A2
(en)
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
US9579324B2
(en)
|
2013-07-11 |
2017-02-28 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
US20150031627A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc |
Therapeutically active compounds and their methods of use
|
SI3030227T1
(sl)
|
2013-08-07 |
2020-08-31 |
Incyte Corporation |
Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
US20160264551A1
(en)
|
2013-10-18 |
2016-09-15 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
CN112159391A
(zh)
|
2014-03-14 |
2021-01-01 |
阿吉奥斯制药公司 |
治疗活性化合物的药物组合物
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
RU2688677C2
(ru)
|
2014-10-24 |
2019-05-22 |
Лэндос Байофарма, Инк. |
Лекарственные средства на основе лантионинсинтетаза с-подобного белка
|
WO2016105528A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
JP6861166B2
(ja)
|
2015-03-27 |
2021-04-21 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
サイクリン依存性キナーゼの阻害剤
|
SI3307271T1
(sl)
|
2015-06-11 |
2023-11-30 |
Agios Pharmaceuticals, Inc. |
Postopki za uporabo aktivatorjev piruvat kinaze
|
WO2016201370A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
EP4019515A1
(en)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
MX2018004586A
(es)
|
2015-10-15 |
2018-08-16 |
Agios Pharmaceuticals Inc |
Terapia de combinacion para tratar tumores malignos.
|
IL258684B2
(en)
|
2015-10-15 |
2023-04-01 |
Agios Pharmaceuticals Inc |
Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3525785A4
(en)
|
2016-10-12 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
KDM5 INHIBITORS
|
WO2018190719A2
(en)
|
2017-04-13 |
2018-10-18 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
JP2020527133A
(ja)
|
2017-06-20 |
2020-09-03 |
インブリア ファーマシューティカルズ, インコーポレイテッド |
心臓代謝の効率を高めるための組成物および方法
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
CN112105608B
(zh)
|
2018-01-30 |
2023-07-14 |
因赛特公司 |
制备(1-(3-氟-2-(三氟甲基)异烟碱基)哌啶-4-酮)的方法
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN110294713B
(zh)
*
|
2018-03-22 |
2022-08-02 |
西华大学 |
一种咪唑甲胺类衍生物的制备方法
|
MX2022012285A
(es)
|
2018-03-30 |
2023-08-15 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
EP3833668A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
WO2020092395A1
(en)
|
2018-10-29 |
2020-05-07 |
Forma Therapeutics, Inc. |
SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
|
MX2022001915A
(es)
|
2019-12-20 |
2022-03-17 |
Landos Biopharma Inc |
Ligandos de proteina 2 tipo lantionina c, celulas preparadas con los mismos y terapias que usan los mismos.
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|